Last updated: February 19, 2026
This report provides a comprehensive analysis of Brazil drug patent application BR112020010185, detailing its scope, specific claims, and the broader patent landscape relevant to its asserted technology. The objective is to equip R&D and investment professionals with actionable intelligence for strategic decision-making.
What is the Core Technology of BR112020010185?
Patent application BR112020010185, filed on May 19, 2020, by MERCK SHARP & DOHME CORP., pertains to new crystalline forms of ertugliflozin. Ertugliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. The application specifically addresses the need for novel crystalline forms of ertugliflozin that offer improved physicochemical properties, such as enhanced stability and processability, compared to previously known forms. These improvements are critical for the efficient manufacturing and reliable therapeutic performance of pharmaceutical products.
The inventors associated with this application are HONG, Jianxin; ZHANG, Jiwen; and HOHENECKER, Kurt. The applicant is identified as MERCK SHARP & DOHME CORP. The application number is BR112020010185, and its publication date was October 19, 2021. The priority date established by the applicant is May 21, 2019, which originates from US patent application US16/418,911. This priority date is crucial for determining the novelty and inventive step of the claimed subject matter against prior art.
The disclosure describes several novel crystalline forms, designated as Form I, Form II, Form III, and Form IV, of ertugliflozin. Each form is characterized by specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) data, and infrared (IR) spectroscopy profiles. These characterization data serve as definitive identifiers for each crystalline form and are central to the patent claims.
For instance, Form I is characterized by specific XRPD peaks at particular 2-theta angles (± 0.2 degrees 2-theta), including but not limited to 8.9, 13.5, 15.1, 20.8, 23.0, and 25.5. DSC data for Form I indicates a melting endotherm with a peak temperature of approximately 143.8 °C. Form II is distinguished by different XRPD peaks and a DSC melting endotherm at approximately 146.5 °C. Similarly, Forms III and IV are defined by their unique diffraction patterns and thermal properties, with Form III exhibiting a DSC melting endotherm at approximately 134.6 °C and Form IV at approximately 136.2 °C.
The application further details the process for obtaining these crystalline forms, often involving specific solvent systems, temperature ranges, and crystallization techniques. These processes are designed to reproducibly yield the desired polymorphic form with high purity and consistent physical attributes.
What are the Specific Claims of BR112020010185?
The claims in patent application BR112020010185 are directed towards protecting the novel crystalline forms of ertugliflozin and pharmaceutical compositions containing them. The claims are meticulously drafted to define the boundaries of the intellectual property protection sought.
Claim 1 is the independent claim, defining a crystalline form of ertugliflozin, hereinafter referred to as Form I, characterized by an X-ray powder diffraction pattern having specific peaks. This claim is critical as it establishes the primary subject of protection as a unique solid-state form of the active pharmaceutical ingredient. The specific XRPD peak positions provided in the claim are the key identifiers of this form.
Claim 2 is dependent on Claim 1 and further specifies the crystalline Form I by its differential scanning calorimetry (DSC) thermogram. This claim adds an additional layer of specificity, requiring the presence of a DSC melting endotherm with a peak temperature of approximately 143.8 °C.
Claim 3 is also dependent on Claim 1 and characterizes Form I by its infrared (IR) spectrum. This claim incorporates specific absorption bands, such as those at approximately 3312, 2973, 1729, 1609, 1457, 1354, 1287, 1155, 1050, 989, 890, 842, 774, 735, and 673 cm-1.
Claim 4 defines a crystalline form of ertugliflozin, hereinafter referred to as Form II, characterized by an X-ray powder diffraction pattern having specific peaks. This claim establishes a second novel crystalline form with its own unique set of XRPD characteristics.
Claim 5 depends on Claim 4 and further specifies Form II by its differential scanning calorimetry (DSC) thermogram, requiring a melting endotherm with a peak temperature of approximately 146.5 °C.
Claim 6 is dependent on Claim 4 and characterizes Form II by its infrared (IR) spectrum, listing specific absorption bands.
Claim 7 defines a crystalline form of ertugliflozin, hereinafter referred to as Form III, characterized by an X-ray powder diffraction pattern having specific peaks.
Claim 8 depends on Claim 7 and further specifies Form III by its differential scanning calorimetry (DSC) thermogram, requiring a melting endotherm with a peak temperature of approximately 134.6 °C.
Claim 9 is dependent on Claim 7 and characterizes Form III by its infrared (IR) spectrum, listing specific absorption bands.
Claim 10 defines a crystalline form of ertugliflozin, hereinafter referred to as Form IV, characterized by an X-ray powder diffraction pattern having specific peaks.
Claim 11 depends on Claim 10 and further specifies Form IV by its differential scanning calorimetry (DSC) thermogram, requiring a melting endotherm with a peak temperature of approximately 136.2 °C.
Claim 12 is dependent on Claim 10 and characterizes Form IV by its infrared (IR) spectrum, listing specific absorption bands.
Claim 13 is a broader claim, reciting a pharmaceutical composition comprising a crystalline form of ertugliflozin as defined in any one of claims 1 to 12, and a pharmaceutically acceptable carrier. This claim protects the use of these novel crystalline forms in finished drug products.
Claim 14 is dependent on Claim 13 and specifies that the crystalline form is ertugliflozin Form I.
Claim 15 is dependent on Claim 13 and specifies that the crystalline form is ertugliflozin Form II.
Claim 16 is dependent on Claim 13 and specifies that the crystalline form is ertugliflozin Form III.
Claim 17 is dependent on Claim 13 and specifies that the crystalline form is ertugliflozin Form IV.
Claim 18 recites a method of treating type 2 diabetes mellitus in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition as defined in Claim 13. This claim covers the therapeutic application of the patented compositions.
The claims are structured to provide broad protection for the identified crystalline forms and their use in pharmaceutical formulations and treatment methods. The specificity of the characterization data (XRPD, DSC, IR) is paramount to defining the novelty and inventive step of each claimed form.
What is the Patent Landscape for Ertugliflozin Crystalline Forms?
The patent landscape surrounding ertugliflozin, particularly concerning its crystalline forms, is characterized by active patenting by the originator and potential challenges from generic manufacturers seeking to enter the market. Understanding this landscape is crucial for assessing freedom-to-operate and identifying potential licensing opportunities or competitive threats.
Key Players and Patent Filings
Merck Sharp & Dohme Corp. (MSD), the applicant of BR112020010185, is the primary patent holder for ertugliflozin and its various forms. The company has strategically filed patents to protect different aspects of the drug, including its chemical synthesis, therapeutic uses, and, critically, its solid-state properties.
Other pharmaceutical companies involved in the diabetes therapeutic area may also hold patents related to SGLT2 inhibitors, which could indirectly impact the ertugliflozin market. However, direct competition for ertugliflozin's core patent protection is primarily concentrated around MSD's filings.
Prior Art and Existing Patents
Prior to the filing of BR112020010185, there were existing patents and scientific literature detailing ertugliflozin. Notably, original patents covering the ertugliflozin molecule itself and its basic therapeutic uses would have been filed earlier. These foundational patents would typically expire before patents on later-discovered crystalline forms.
For example, U.S. Patent 8,575,349 B2, granted to Merck & Co., Inc. on November 5, 2013, broadly covers compounds for treating hyperglycemia, including ertugliflozin. This type of patent provides the initial market exclusivity for the active ingredient.
The emergence of patents like BR112020010185 reflects a common pharmaceutical patenting strategy where companies seek to extend market exclusivity by patenting new, improved, or easier-to-manufacture forms of an existing drug. These "polymorph patents" are often litigated, as they can significantly influence the timeline for generic market entry.
The Significance of Polymorph Patents
The patent landscape for ertugliflozin crystalline forms is particularly relevant due to the importance of polymorphism in pharmaceuticals. Different crystalline forms (polymorphs) of the same active pharmaceutical ingredient (API) can exhibit distinct physical properties, including:
- Solubility and Dissolution Rate: Affecting bioavailability and efficacy.
- Stability: Influencing shelf life and degradation pathways.
- Hygroscopicity: Impacting handling and formulation.
- Compressibility and Flowability: Critical for tablet manufacturing.
By patenting novel crystalline forms with advantageous properties, MSD aims to prevent generic competitors from marketing their own versions of ertugliflozin, even after the expiration of the original compound patent, if those generic versions utilize a different, unpatented crystalline form or if the patented form is essential for an effective and stable formulation.
Potential for Generic Challenges
Generic drug manufacturers typically seek to produce a bioequivalent version of a branded drug after patent expiry. For ertugliflozin, this involves identifying crystalline forms that are not covered by existing patents and can be manufactured cost-effectively.
Generic companies will meticulously examine the patents protecting ertugliflozin's crystalline forms, such as BR112020010185. Their strategy often involves:
- Identifying non-infringing crystalline forms: Searching for or developing new polymorphic forms of ertugliflozin that are not claimed in any active patents.
- Challenging the validity of existing patents: Attempting to invalidate polymorph patents by demonstrating that the claimed forms were known, obvious, or not sufficiently distinct from prior art.
- Developing alternative formulations: Even if a specific crystalline form is patented, it may be possible to develop a formulation using that form under license or after the patent expires.
The detailed characterization data (XRPD, DSC, IR) provided in BR112020010185 is crucial for enforcing these patents. Competitors must demonstrate that their crystalline forms are structurally different from the claimed forms to avoid infringement.
Geographical Considerations
The patent landscape is global. While BR112020010185 pertains to Brazil, similar patent applications and grants would have been sought in other major pharmaceutical markets, including the United States, Europe, Japan, and China. A comprehensive landscape analysis would require examining patent filings in all relevant jurisdictions. The patent term for BR112020010185, once granted, will be 20 years from the filing date (May 19, 2020), subject to potential extensions for pharmaceutical products in some jurisdictions.
Summary of Landscape
The patent landscape for ertugliflozin crystalline forms is a critical area for both originator and generic pharmaceutical companies. MSD's application BR112020010185 represents a strategic effort to reinforce its market position by protecting specific, potentially improved, crystalline forms of ertugliflozin. Generic players will scrutinize these patents for weaknesses or opportunities to develop non-infringing alternatives, setting the stage for potential patent litigation and market entry strategies.
Key Takeaways
- BR112020010185 protects novel crystalline forms of ertugliflozin (Forms I, II, III, and IV), distinguished by specific XRPD, DSC, and IR data, aiming to improve stability and manufacturing.
- The claims cover the crystalline forms themselves, pharmaceutical compositions containing them, and methods of treating type 2 diabetes mellitus using these compositions.
- Merck Sharp & Dohme Corp. is the applicant, with a priority date of May 21, 2019.
- The patent landscape involves strategic polymorph patenting by the originator to extend market exclusivity and potential challenges from generic manufacturers seeking alternative crystalline forms or invalidating existing patents.
- The application and its corresponding granted patents, if any, are critical for assessing freedom-to-operate for any entity wishing to market ertugliflozin in Brazil.
Frequently Asked Questions
-
What is the primary benefit of patenting new crystalline forms of a drug like ertugliflozin?
Patenting new crystalline forms can extend market exclusivity beyond the expiry of the original compound patent by protecting improved versions of the active pharmaceutical ingredient that may offer better stability, manufacturing efficiency, or bioavailability.
-
How are the crystalline forms in BR112020010185 distinguished from each other and from known forms?
Each crystalline form is uniquely identified by its specific X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) thermogram, and infrared (IR) spectroscopy profile. These distinct physical characteristics are listed in the patent claims.
-
What is the earliest possible date for patent protection for BR112020010185 in Brazil?
The earliest possible date for patent protection in Brazil, based on the application's priority date, is May 21, 2019. The patent term is generally 20 years from the filing date of May 19, 2020.
-
Can a generic company launch an ertugliflozin product in Brazil if this patent application is granted?
A generic company's ability to launch depends on whether their product infringes any granted claims. If BR112020010185 grants and protects the specific crystalline form used by the generic, then a launch would be blocked unless the patent is invalidated or a license is obtained. Generic companies may attempt to use alternative, non-infringing crystalline forms.
-
What is the significance of the SGLT2 inhibitor class in the context of this patent?
Ertugliflozin belongs to the SGLT2 inhibitor class, a significant category of drugs for managing type 2 diabetes. This patent is part of a broader strategy by pharmaceutical companies to protect their investments in developing and marketing drugs within this class, often through a portfolio of patents covering the molecule, its manufacturing, formulations, and various solid-state forms.
Citations
[1] MERCK SHARP & DOHME CORP. (2021, October 19). Ertugliflozin crystalline forms. Brazil Patent Application BR112020010185.
[2] MERCK & CO. (2013, November 5). Compounds for treating hyperglycemia. U.S. Patent 8,575,349 B2.
